Market research
NURO NeuroMetrix Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 9M
- P/E ratio
- Not available
- Analyst target
- 50
- Dividend yield
- Not available
- Beta
- 1.83
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- US6412558073
- Market cap
- 9M
- P/E ratio
- Not available
- Analyst target
- 50
- Dividend yield
- Not available
- Beta
- 1.83
About
About NeuroMetrix Inc
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing and sale of medical devices. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; and Quell, a wearable device for symptomatic relief and management of chronic pain. The company offers its products to managed endocrinologists, podiatrists, primary care physicians, and other clinicians at the point-of care to objectively detect, stage, and monitor peripheral neuropathies. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the NURO discussion.
5 years, 4 months ago
NeuroMetrix, Inc is currently in a long term uptrend where the price is trading 14.0% above its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.4.
NeuroMetrix, Inc's total revenue rose by 6.0% to $2M since the same quarter in the previous year.
Its net income has increased by 100.2% to $2K since the same quarter in the previous year.
Finally, its free cash flow grew by 513.3% to $281K since the same quarter in the previous year.
Based on the above factors, NeuroMetrix, Inc gets an overall score of 5/5.